Karl Bonney

Karl Bonney is a highly experienced medicinal chemist with a robust background in pharmaceutical research and development. Currently serving as a Senior Research Scientist III at Xellia Pharmaceuticals since August 2019, Karl focuses on anti-infective treatments for severe infections. Previous roles include Senior Scientist at Arctic Pharma AS, where Karl led the drug development process for novel small molecule inhibitors against glycolytic cancers, and positions at Xellia Pharmaceuticals and Lundbeck, contributing to the development of treatments for multi-drug resistant bacteria and CNS disorders, respectively. Karl's academic credentials include a PhD and MSc in Chemistry from Imperial College London, complemented by postdoctoral fellowships at RWTH Aachen University and ETH Zurich, specializing in trifluoromethylation methodologies and palladium-catalysis.